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Aim: To evaluate the safety and tolerability of dapagliflozin, a highly selective sodium-glucose
co-transporter-2 inhibitor, in patients with type 2 diabetes mellitus (T2DM).
Methods: Data were pooled from 13 placebo-controlled trials of up to 24 weeks’ duration
(dapagliflozin, n = 2360; placebo, n = 2295). Larger placebo-/comparator-controlled pools of
21 (≤208 weeks; dapagliflozin, n = 5936; control, n = 3403) and 30 trials (≥12 weeks; dapagli-
flozin, n = 9195; control, n = 4629) assessed the rare adverse events (AEs) of diabetic ketoaci-
dosis (DKA) and lower limb amputation, respectively.
Results: Over 24 weeks, the overall incidence of AEs and serious AEs (SAEs) was similar for
dapagliflozin and placebo: 60.0% vs 55.7% and 5.1% vs 5.4%, respectively. Rates of hypogly-
caemia, volume depletion AEs, urinary tract infections (UTIs) and fractures were balanced
between the groups. Genital infections were more frequent with dapagliflozin (5.5%) vs pla-
cebo (0.6%) and renal function AEs occurred in 3.2% vs 1.8% of patients (the most common
renal AE was decreased creatinine clearance: 1.1% vs 0.7%). In the 21-study pool, 1 SAE of
DKA and 3 AEs of ketonuria/metabolic acidosis occurred with dapagliflozin vs none with con-
trol; estimated combined incidence for these events was 0.03% (95% confidence interval
0.010-0.089). In the 30-study pool, lower limb amputation occurred in 8 (0.1%) and 7 (0.2%)
patients receiving dapagliflozin and control, respectively.
Conclusion: The overall incidence rates of AEs and SAEs were similar in the dapagliflozin and
placebo/control groups, including the incidence of hypoglycaemia, volume depletion, fractures,
UTIs, amputations and DKA. Genital infections were more frequent with dapagliflozin than
placebo.
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1 | INTRODUCTION
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a newer class
of antihyperglycaemic agents that not only lower blood glucose
levels, body weight and systolic blood pressure, but have also
recently demonstrated cardiovascular (CV) safety.1,2 The safety of
these agents is of keen interest to physicians treating patients with
type 2 diabetes mellitus (T2DM). Common adverse events (AEs) have
been associated with the use of SGLT2 inhibitors such as genital
infection, urinary tract infection (UTI) and polyuria.3
Dapagliflozin is a highly selective SGLT2 inhibitor that lowers
blood glucose levels in an insulin-independent manner by suppressing
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renal glucose reabsorption and increasing urinary glucose
excretion.4–6 In phase III trials, dapagliflozin was efficacious and well
tolerated in the early and late stages of T2DM, with no major imbal-
ances in safety events observed between the dapagliflozin and con-
trol arms.7–11
Although the CV safety of SGLT2 inhibitors has been confirmed in
recent outcome trials, pooled analyses of these agents have previously
shown differing overall safety profiles. Empagliflozin was well tolerated
with no increase in the risk of hypoglycaemia (except in patients on
background sulphonylureas) and UTI and volume depletion (except in
patients aged ≥75 years, where a higher incidence was observed with
both empagliflozin 10 and 25 mg) compared with placebo.12,13 Low
rates of bone fractures, AEs consistent with decreased renal function
and diabetic ketoacidosis (DKA) were observed in the empagliflozin
and placebo groups.12,13 Small increases in serum creatinine and small
decreases in estimated glomerular filtration rate (eGFR) were noted
across the overall pool of patients, with larger changes in the empagli-
flozin groups compared with placebo. Genital infections were more fre-
quent with empagliflozin vs placebo. Canagliflozin was associated with
a slightly higher incidence of hypoglycaemia vs the comparator. Also,
higher incidences of genital infections, UTI and AEs related to volume
depletion were observed with canagliflozin vs comparator.14 The inci-
dence rates of fractures and DKA were low in the canagliflozin and
comparator groups.14
Over the past couple of years, drug safety communications
regarding the risk of DKA, fracture and serious UTIs of pyelonephritis,
urosepsis and acute kidney injury related to the use of SGLT2 inhibi-
tors have been issued by the US Food and Drug Administration
(FDA).15,16 Another drug safety communication was also issued more
recently regarding the potential for an increased risk of lower limb
amputation (mostly affecting the toes) in patients receiving
canagliflozin,17 prompted by an increase in lower limb amputation
reported in an interim analysis of the CANVAS trial in patients with
T2DM with a history/risk of CV disease.18 This was further con-
firmed in the final analysis of the CANVAS programme, which
showed increased risk of lower limb amputation with canagliflozin vs
placebo (6.3 vs 3.4 per 1000 patient-years; hazard ratio 1.97; 95%
confidence interval [CI] 1.41 to 2.75).1
The present analysis builds on a previous publication on the safety
of dapagliflozin19 by evaluating the safety and tolerability of dapagliflo-
zin in a larger pool of studies and reporting the incidence of amputa-
tion and DKA, which were not included in the previous analyses.
2 | METHODS
2.1 | Patient population
Three pooled patient populations were included in this analysis. The
majority of AEs were evaluated using pooled data from 13 placebo-
controlled, double-blind, phase IIb/III studies of up to 24 weeks’ dura-
tion (Figure S1), in which patients with T2DM were randomized to
receive dapagliflozin 10 mg (N = 2360) or placebo (N = 2295). This
included 3 phase IIb studies of 12 weeks’ duration, and 10 phase III
studies of 24 weeks’ duration. The placebo-controlled pool was
analysed to better enable identification of any difference in the fre-
quency of AEs with dapagliflozin vs placebo. (ClinicalTrials.gov identi-
fiers: NCT00263276, NCT00357370, NCT00528372, NCT00528879,
NCT00643851, NCT00660907, NCT00663260, NCT00831779,
NCT00673231, NCT00680745, NCT00683878, NCT00736879,
NCT00855166, NCT00859898, NCT00972244, NCT00976495,
NCT00984867, NCT01031680, NCT01042977, NCT01095653,
NCT01095666, NCT01137474, NCT01195662, NCT01217892,
NCT01294423, NCT01294436, NCT01392677, NCT01606007,
NCT01619059, NCT01646320)
Two larger and longer-term pools were used to evaluate the inci-
dence of DKA and amputation, which are both rare events. The
greater number of patient-years included in these pools increased the
odds of observing these events. A pool of 21 placebo-/active
comparator-controlled trials (≤208 weeks; dapagliflozin [N = 5936]
and placebo/active comparator [N = 3403]) was used to assess DKA
(Figure S2) and a pool of 30 placebo-/active comparator-controlled
trials (≥12 weeks; dapagliflozin [N = 9195] and placebo/active com-
parator [N = 4629]) was used to assess lower limb amputation
(Figure S3). The 21-study pool had the same data cut as for the 13-
study pool. Additional studies were analysed for amputations that
were not part of the dapagliflozin clinical programme (such as those
with a study group receiving saxagliptin plus dapagliflozin). In these
two pools, the doses of dapagliflozin given across all studies were
2.5, 5, 10, 20 and 50 mg; however, dapagliflozin 5 and 10 mg were
the most frequently used doses.
2.2 | Outcomes
The outcomes analysed in the 13-study pool were overall AEs and
serious AEs (SAEs), AEs occurring in ≥3% of the pooled population,
and AEs of hypoglycaemia, renal function, volume depletion, UTI,
genital infection and fracture. Change in the eGFR (calculated using
the Modification in Diet and Renal Disease formula) over time and
changes in the plasma lipid profile were also evaluated in the 13-
study pool. DKA and lower limb amputation were evaluated in the
21- and 30-study pools, respectively. Although AEs of special interest
were not independently adjudicated, they were identified based on
prespecified lists of Medical Dictionary for Regulatory Activities
(MedDRA version 15.1) predefined terms. Amputation events were
identified by free-text searches in individual study databases and clin-
ical study reports.
Events of hypoglycaemia were categorized into major, minor or
other. Major episodes were defined as symptomatic episodes requir-
ing third-party assistance because of severe impairment in conscious-
ness or behaviour, with a capillary or plasma glucose value
<3 mmol/L and a prompt recovery after glucose or glucagon adminis-
tration. Minor episodes were defined as either symptomatic, with a
capillary or plasma glucose measurement <3.5 mmol/L regardless of
need for external assistance, or asymptomatic, with a capillary or
plasma glucose value <3.5 mmol/L and not qualifying as a major epi-
sode. Other episodes of hypoglycaemia were defined as reported
suggestive episodes but did not meet the criteria for major or minor
episodes.
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2.3 | Statistical analysis
All patients who received at least 1 dose of study treatment were
included in the analyses. The analyses were post hoc and no statisti-
cal hypothesis testing was performed. Descriptive statistics were
used to describe safety parameters and all analyses were performed
using all available data regardless of rescue during the specified treat-
ment period.
2.4 | Ethical approval
All studies were conducted in accordance with the ethical standards
of the institutional and/or national research committee and with the
1964 Helsinki declaration and its later amendments or comparable
ethical standards. All enrolled patients provided written informed
consent before entering the trial.
3 | RESULTS
3.1 | Patient disposition
Patient baseline characteristics were generally similar in the dapagli-
flozin and control groups in the studies included in the 3 study pools
(data for the 13- and 21-study pools are shown in Table S1). As data
for the 30 studies were not formally pooled, baseline data tables are
not available for this pool. In the 13-study pool, at baseline, the mean
duration since T2DM diagnosis was 8.9 years, the mean glycated
haemoglobin (HbA1c) value was 8.2% (66 mmol/mol), the mean sys-
tolic blood pressure was 132 mm Hg and the majority of patients
(>85%) had an eGFR ≥60 mL/min/1.73 m2. Over 90% of patients had
a body mass index ≥25 kg/m2. Overall, 10.0% and 11.6% of
dapagliflozin- and placebo-treated patients, respectively, were treated
with loop diuretics.
3.2 | Overall AEs: 13-study pool
The overall incidence of AEs is shown in Table 1. The proportions of
patients reporting ≥1 AE were 60.0% and 55.7% in the dapagliflozin
and placebo groups, respectively. Most events were not serious, were
considered not related to study drug, and did not lead to study dis-
continuation. SAEs occurred in 5.1% and 5.4% of patients, respec-
tively, and death was an infrequent event with similar occurrence in
each group.
3.3 | AEs of special interest: 13-study pool
3.3.1 | Hypoglycaemia
The overall incidence of hypoglycaemia was 13.7% and 12.4% with
dapagliflozin and placebo, respectively (Table 2). Major hypoglycae-
mia occurred infrequently, with 3 and 2 events reported with dapagli-
flozin and placebo, respectively. Most of the events of major
hypoglycaemia occurred in patients receiving insulin as background
therapy. Only 1 patient in the dapagliflozin group discontinued treat-
ment because of hypoglycaemia. This patient was receiving dapagli-
flozin added to insulin and metformin, and discontinued treatment
after reporting major hypoglycaemia on day 107.
3.3.2 | AEs of renal function
Overall, AEs of renal function were reported in 76 (3.2%) and 42 (1.8%)
patients receiving dapagliflozin and placebo, respectively. A greater num-
ber of events of decreased renal creatinine clearance or renal impair-
ment were observed with dapagliflozin (Table 2; Table S2); however,
most events were transient, of mild/moderate intensity, and not accom-
panied by marked abnormalities of renal function (data not shown). The
proportion of patients reporting AEs of renal function was larger in the
subgroup with baseline eGFR of 30 to <60 mL/min/1.73 m2 than in the
subgroup with eGFR ≥60 mL/min/1.73 m2 (Table S2). When stratified
by age, AEs of renal function were more frequent in patients aged
≥65 years than in those aged <65 years (Table S2).
In patients receiving dapagliflozin, there was an initial decline in
eGFR at week 1 (Figure 1), followed by a return towards baseline
levels over time (mean change from baseline at week 24: −1.45 and
−0.67 mL/min/1.73 m2 with dapagliflozin and placebo, respectively).
The change from baseline over time was consistent in the overall
study population and in patients with baseline eGFR ≥60 mL/min/
1.73 m2; however, compared with patients with a higher baseline
eGFR, dapagliflozin-treated patients with an eGFR of 30 to <60 mL/
min/1.73 m2 had a smaller reduction in eGFR at week 1, which
returned to baseline by week 4 (Figure S4).
3.3.3 | Volume depletion
The incidence of AEs of volume depletion (hypotension/hypovolemia/
dehydration) was 1.1% and 0.7% with dapagliflozin and placebo,
respectively (Table 2). In both treatment groups, half of the AEs of vol-
ume depletion occurred by week 8, with 18.5% (5/27) and 17.6%
(3/17) occurring during the first 2 weeks of treatment in the dapagliflo-
zin and placebo groups, respectively. When stratified by age, the fre-
quency of AEs of volume depletion was similar in patients aged <65
and ≥65 years in the placebo group, whereas in the dapagliflozin
TABLE 1 Summary of overall AEs (13-study pool)
Placebo group
(N = 2295; 957.9
patient-years) n (%)
Dapagliflozin
10 mg group
(N = 2360; 997.6
patient-years)
n (%)
≥1 AE 1279 (55.7) 1416 (60.0)
AE leading to
discontinuation
82 (3.6) 102 (4.3)
≥1 SAE 123 (5.4) 120 (5.1)
SAE leading to
discontinuation
24 (1.0) 16 (0.7)
Deaths 4 (0.2) 7 (0.3)
Most common adverse events (≥3% in either treatment group)
Nasopharyngitis 133 (5.8) 126 (5.3)
Diarrhoea 87 (3.8) 79 (3.3)
Headache 83 (3.6) 81 (3.4)
Upper
respiratory
tract infection
91 (4.0) 72 (3.1)
UTI 61 (2.7) 91 (3.9)
Back pain 56 (2.4) 83 (3.5)
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TABLE 2 Summary of AEs of special interest (13-, 21- and 30-study pools)
Placebo-controlled 13-study poola
Placebo group
(N = 2295; 957.9 patient-years)
Dapagliflozin 10 mg group
(N = 2360; 997.6 patient-years)
Hypoglycaemia, n (%) 284 (12.4) 324 (13.7)
Major episode 2 (0.1) 3 (0.1)
Leading to discontinuation 0 1 (<0.1)
AEs of renal functionb, n (%) 42 (1.8) 76 (3.2)
Most common renal function AEs (>1 patient in either treatment group), n (%)
Creatinine renal clearance decreased 16 (0.7) 27 (1.1)
Renal impairment 12 (0.5) 20 (0.8)
Blood creatinine increased 9 (0.4) 15 (0.6)
eGFR decreased 3 (0.1) 7 (0.3)
Renal failure 2 (0.1) 4 (0.2)
Renal failure acute 1 (<0.1) 3 (0.1)
Volume depletion AEsc, n (%) 17 (0.7) 27 (1.1)
Most common volume depletion AEs (>1 patient in either treatment group), n (%)
Hypotension 5 (0.2) 15 (0.6)
Syncope 3 (0.1) 6 (0.3)
Orthostatic hypotension 6 (0.3) 2 (0.1)
Dehydration 0 2 (0.1)
UTI, n (%) 81 (3.5) 110 (4.7)
Most common UTI AEs (>1 patient in either treatment group), n (%)
UTI 61 (2.7) 91 (3.9)
Cystitis 15 (0.7) 16 (0.7)
Prostatitis 3 (0.1) 0
Genital infection, n (%) 14 (0.6) 130 (5.5)
Most common genital infection AEs (>1 patient in either treatment group), n (%)
Vulvovaginal mycotic infection 7 (0.3) 34 (1.4)
Balanitis 0 29 (1.2)
Vaginal infection 1 (<0.1) 18 (0.8)
Genital infection fungal 2 (0.1) 12 (0.5)
Genital infection 1 (<0.1) 11 (0.5)
Vulvovaginal candidiasis 1 (<0.1) 8 (0.3)
Balanitis candida 0 6 (0.3)
Vulvovaginitis 0 5 (0.2)
Genital candidiasis 0 3 (0.1)
Vulvitis 0 2 (0.1)
Fractures, n (%) 17 (0.7) 8 (0.3)
Potential events of DKA
Placebo/comparator-controlled 21-study pool
Control
(N = 3403; 3637.6 patient-years)
Dapagliflozin total
(N = 5936; 6247.2 patient-years)
SAE of DKA, n 0 1
AE of ketonuria, n 0 2
AE of metabolic acidosis, n 0 1
Estimated incidence of DKA, % (95% CI) 0 0.02 (0.004, 0.059)
Estimated incidence of DKA/metabolic acidosis, % (95% CI) 0 0.03 (0.010, 0.089)
Amputation
Placebo/comparator-controlled 30-study pool
Control
(N = 4629; 4177 patient-years)
Dapagliflozin total
(N = 9195; 8059 patient-years)
Patients with lower-limb amputation, n (%) 7 (0.2) 8 (0.1)
Dapagliflozin total includes dapagliflozin 2.5, 5, 10, 20 and 50 mg groups combined. Control includes placebo with/without background medications or active
control including conventional treatments; major episode of hypoglycaemia was defined as glucose <3 mmol/L (<54 mg/dL) requiring third-party assistance.
a Including data after rescue.
b Renal function AEs include renal failure or impairment, creatinine renal clearance decreased/increased/abnormal, blood creatinine increased/decreased,
eGFR decreased/increased/abnormal, cystatin C increased, renal function test abnormal, urine flow or output decreased/increased/abnormal, anuria.
c Volume depletion AEs include hypotension/hypovolemia/dehydration.
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group, patients aged ≥65 years were more likely to have an AE of vol-
ume depletion (Table S3). The frequency of AEs of volume depletion in
patients using loop diuretics was 2.5 times higher than in patients not
using them in both treatment groups (Table S3). In addition, AEs of vol-
ume depletion occurred less frequently in patients with baseline eGFR
≥60 mL/min/1.73 m2 than in those with baseline eGFR 30 to <60 mL/
min/1.73 m2 regardless of the treatment group (Table S3).
Hypotension was the most common AE of volume depletion in
both treatment groups; however, most events were considered unre-
lated to study drug, were of mild/moderate intensity and did not require
drug interruption/discontinuation. Syncope was the second most fre-
quently reported AE of volume depletion, with episodes of syncope dis-
tributed throughout the 24-week treatment period (Table S4).
3.3.4 | Urinary tract infection
The occurrence of UTI was 4.7% and 3.5% with dapagliflozin and pla-
cebo, respectively (Table 2), and UTIs were more frequent in women
than men in both treatment groups (Table S5). The majority of UTIs
were mild/moderate in intensity, and UTI-related discontinuations
were infrequent and similar to dapagliflozin and placebo (5 [0.2%]
and 2 [0.1%], respectively). Most patients in both treatment groups
responded to initial antimicrobial treatment without requiring any
additional treatment. Most UTIs had flora consistent with those
found in patients with T2DM and were not kidney infections. Fur-
thermore, of the patients who reported UTIs, 26 (23.6%) and
24 (29.6%) patients in the dapagliflozin and placebo groups, respec-
tively, had a medical history of UTI (Table S5).
3.3.5 | Genital infection
Genital infections were more frequent with dapagliflozin vs placebo
(5.5% vs 0.6%). More women than men experienced genital infections
in both treatment groups (Table S5). All events were mild/moderate in
intensity and discontinuations because of genital infections were
reported for 5 (0.2%) patients treated with dapagliflozin (vulvovaginal
mycotic infection [3 patients], balanitis [1 patient] and vulvovaginal
candidiasis [1 patient]) and no patient receiving placebo. In both treat-
ment groups, most patients with genital infections (≥80%) responded
to initial antimicrobial treatment and did not need additional treat-
ment. Of the patients who reported genital infections, 8 (6.2%) and 2
(14.3%) patients in the dapagliflozin and placebo groups, respectively,
had a medical history of recurrent yeast infection (Table S5).
3.3.6 | Fracture
The proportion of patients reporting fractures was small in both the
dapagliflozin (8 [0.3%]) and placebo (17 [0.7%]) groups (Table 2). The
most common fracture locations were the foot, ankle, femoral neck,
hand, radius, upper limb and spine (Table S6). There was no consis-
tent pattern to fracture location in either group.
3.3.7 | Lipids
Small mean increases from baseline in HDL cholesterol (0.07 mmol/L),
LDL cholesterol (0.07 mmol/L) and total cholesterol (0.11 mmol/L)
were observed, whereas a small decrease in triglycerides (−0.07 mmol/
L) was noted (Table S7).
3.4 | DKA: 21-study pool
One SAE of DKA, 2 AEs of ketonuria and 1 AE of metabolic acidosis
were reported in the dapagliflozin group and none in the control
group (Table 2). The estimated incidence of DKA/metabolic acidosis
with dapagliflozin was 0.03% (95% CI 0.010-0.089) and the estimated
incidence of DKA alone was 0.02% (95% CI 0.004-0.059). The SAE of
DKA occurred in a patient who was receiving dapagliflozin 10 mg
added to metformin and insulin. An event of gastroenteritis was also
recorded in this patient on the same day (day 214), and both DKA
and gastroenteritis were considered unrelated to the study drug.
Treatment was continued after the event resolved.
3.5 | Amputation: 30-study pool
Lower limb amputation (ie, leg and foot amputation, mostly affecting
the toes) was reported for 8 (0.1%) and 7 (0.2%) dapagliflozin- and
control-treated patients, respectively (Table 2). There were no apparent
between-group differences in the baseline characteristics of patients
who had an amputation. In both groups, patients who had an amputa-
tion had a high prevalence of risk factors for amputation, including
neuropathy, CV disease, dyslipidaemia and nephropathy. Time to
amputation was similar for dapagliflozin- and control-treated patients.
In the dapagliflozin group, the onset of events occurred >150 days
after initiation of study treatment in the majority (5/8) of patients.
FIGURE 1 Values for eGFR over time
(13-study pool). eGFR was calculated
using the Modification in Diet and
Renal Disease (MDRD) formula. BL,
baseline; s.e., standard error. Patients at
baseline denote the number of treated
patients with non-missing baseline
values
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4 | DISCUSSION
This pooled analysis reports the safety findings for dapagliflozin,
including the newer emergent safety issues of ketoacidosis and lower
limb amputation, thereby adding to the knowledge of the safety of
this agent in patients with T2DM. This analysis identified no new
safety signals for dapagliflozin.
The risk of hypoglycaemia associated with SGLT2 inhibitors is low,
as suggested by their mechanism of action and clinical experience to
date, and a similar incidence of hypoglycaemia was observed between
dapagliflozin and placebo in the analysis reported here. In a pooled anal-
ysis of empagliflozin trials, 23.1%, 22.7% and 22.7% of patients receiv-
ing empagliflozin 10 and 25 mg and placebo, respectively, reported AEs
of hypoglycaemia.12 In a pooled analysis of canagliflozin trials, AEs of
hypoglycaemia were reported for 6.9%, 4.1% and 2.9% of patients
receiving canagliflozin 100 and 300 mg, and placebo, respectively, as
monotherapy, and for 44.4%, 49.4%, and 34.0% of patients, respec-
tively, who were also receiving background antihyperglycaemic drugs.14
Renal function AEs were observed with dapagliflozin in the pre-
sent analysis. AEs consistent with decreased renal function have also
been shown with other SGLT2 inhibitors (1.8, 1.8 and 2.2 per 100
patient-years with empagliflozin 10 and 25 mg and placebo, respec-
tively [events consistent with decreased renal function, based on nar-
row standardised MedDRA queries acute renal failure],13 and 2.1, 2.5
and 2.6 per 100 patient-years with canagliflozin 100 and 300 mg and
control,14 respectively). It is worth noting that there are differences
in the clinical trial programmes for each SGLT2 inhibitor regarding
the definition of AEs of renal function, the requirements for labora-
tory testing, and the criteria for discontinuation and reporting of AEs
based on laboratory values.
The AEs of renal function observed with dapagliflozin were pri-
marily associated with transient changes in serum creatinine or
renal creatinine clearance, and were rarely associated with SAEs of
renal failure or marked abnormalities of serum creatinine >2.5 g/dL
(data not shown). Notably, some of the dapagliflozin studies had
protocol-specific discontinuation requirements for patients with
confirmed calculated creatinine clearance that decreased below a
specific level (this level varied across studies) and/or increases in
serum creatinine. The AEs of renal function were recorded cumula-
tively over the 24-week treatment period; it can be speculated that
the initial decline in eGFR may have been recorded as an AE
although eGFR levels returned towards baseline over time. The
early, transient changes were not indicative of progressive renal
dysfunction, however, as demonstrated by the gradual increase
towards baseline in eGFR over time. It has been postulated that
the transient decreases in eGFR relate to the haemodynamic
changes resulting from diuresis and a reduction in blood pressure.20
Furthermore, SGLT2 inhibition restricts proximal tubular reabsorp-
tion of glucose and sodium, leading to increased sodium delivery to
the macula densa that alters tubuloglomerular feedback causing
renal glomerular afferent vasoconstriction. This may have also con-
tributed to the initial decline in eGFR, which subsequently returns
to baseline once the initial transient natriuresis observed with
dapagliflozin resolved.21,22
In our pooled analysis, eGFR did not return to baseline in the overall
population treated with dapagliflozin, possibly because of the relatively
short duration of treatment; however, in longer-term dapagliflozin stud-
ies, the initial decline in eGFR was observed to return to near- or
above-baseline levels by week 24 that remained stable to week 102.23
This finding correlates with the findings noted in the empagliflozin and
canagliflozin trials. In the EMPA-REG OUTCOME trial, a short-term
eGFR decrease followed by stabilization over time was observed for
empagliflozin (median treatment duration 2.6 years, median observation
time 3.1 years).24 Likewise, an initial decrease in eGFR (3-6 weeks)
that attenuated over time has also been observed for canagliflozin.25
Osmotic diuresis caused by SGLT2 inhibition may potentially lead
to volume depletion in susceptible patients; however, the incidence
of volume depletion was low in our analysis and analyses of the cur-
rently marketed SGLT2 inhibitors have demonstrated that the risk of
these events lessens over time.14,26 The incidence of events of vol-
ume depletion was observed to be low with empagliflozin 10 and
25 mg and placebo (1.8, 1.9 and 1.7 per 100 patient-years, respec-
tively), with an increased incidence of events observed in patients
aged ≥75 years (3.2, 3.0 and 2.3 per 100 patient-years, respectively)
and those receiving loop diuretics (5.0, 4.4 and 3.5 per 100 patient-
years, respectively).13 The incidence of events of volume depletion
over 104 weeks was 2.9%, 3.6% and 2.1% with canagliflozin 100 and
300 mg and control, respectively.14 In the CANVAS trial, the inci-
dence of events of volume depletion was 26.0 vs 18.5 per 1000
patient-years with canagliflozin vs placebo, respectively.1 While vol-
ume depletion was low with dapagliflozin and empagliflozin, there is
need for caution when prescribing an SGLT2 inhibitor to the elderly
and those receiving loop diuretics.
Clinical trials show that SGLT2 inhibitors are associated with an
increased risk of genital infections; however, clinical data on the asso-
ciated risk of UTIs are less consistent. In our analysis, no increase in
the risk of UTIs was observed with dapagliflozin vs placebo. The pro-
portions of patients reporting UTIs were 15.1%, 14.5% and 15.0%
with empagliflozin 10 and 25 mg and placebo, respectively.13 The
incidence rates of UTIs were 7.7, 6.8 and 6.4 per 100 patient-years
with canagliflozin 100 and 300 mg and placebo, respectively.14
The incidence of genital infection was higher with dapagliflozin vs
control in the present analysis, and this is consistent with other analyses
of dapagliflozin, empagliflozin and canagliflozin.2,12–14,19,27 A meta-
analysis comparing all SGLT2 inhibitors with placebo observed a 4 to
6 times increased risk of genital infection with SGLT2 inhibitor use.28
There is an increased risk of fracture in patients with T2DM, and
some anti-hyperglycaemic therapies (eg, thiazolidinediones) may fur-
ther exacerbate this.29 SGLT2 inhibition has the potential to increase
serum phosphate levels, which has been hypothesized to exert
adverse effects on bone30; however, in this pooled analysis, dapagli-
flozin did not increase fracture risk vs control. Furthermore, no clini-
cally meaningful changes in bone minerals including calcium,
inorganic phosphorus and 25-hydroxyvitamin D have been reported
with dapagliflozin vs placebo.31
No increased incidence of fracture was observed in pooled analyses
comparing empagliflozin 10 and 25 mg and placebo (2.8, 2.5 and 2.9
per 100 patient-years, respectively)13 or canagliflozin 100 and 300 mg
and control (1.2, 1.4 and 1.1 per 100 patient-years, respectively)14;
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however, the FDA has previously strengthened the drug safety warn-
ings for canagliflozin relating to fracture owing to a higher incidence of
fracture observed with canagliflozin vs placebo in an interim analysis of
the CANVAS trial.18 This was confirmed by the final analysis of the
CANVAS trial in patients with a history of CV disease or at high CV risk,
which showed higher fracture rates with canagliflozin vs placebo (16.9
vs 10.9 per 1000 patient-years; hazard ratio 1.55; 95% CI 1.21-1.97)1;
however, the CANVAS-R (CANVAS-Renal) trial in patients with a his-
tory of CV disease or at high CV risk1 and other canagliflozin studies
that enrolled a general diabetes population have not shown any differ-
ences in fracture risk with canagliflozin vs control.32
Small mean changes in lipid variables were observed in the pre-
sent analysis; however, these changes were not considered to be clin-
ically meaningful. Likewise, small changes in lipids were noted in the
pooled analysis of empagliflozin trials.13 Canagliflozin showed
increases in LDL cholesterol, non-HDL cholesterol and HDL choles-
terol compared with control14; however, CV safety of canagliflozin
has been confirmed in the recent CV outcomes trial (CANVAS) in
patients with T2DM and high CV risk.1
Post-marketing reports of SGLT2 inhibitor-associated ketoacido-
sis33 resulted in the FDA issuing a safety communication concerning
euglycaemic ketoacidosis in patients receiving SGLT2 inhibitors. The
American Association of Clinical Endocrinologists and American Col-
lege of Endocrinology subsequently released a position statement34
that highlighted the need to fully understand the mechanisms of the
metabolic effect of SGLT2 inhibitors, with a focus on analysing the
potential problem of DKA with lower-than-anticipated glucose levels.
In the present analysis, there was only 1 reported SAE of DKA. It
may have occurred in response to insulin dose reduction, which is
considered as a precipitant of DKA.34 In a pooled analysis of empagli-
flozin studies (n = 12 620), incidence rates of DKA were 0.1 (n = 5),
<0.1 (n = 1) and 0.1 (n = 5) per 100 patient-years with empagliflozin
10 and 25 mg and placebo, respectively.13 In clinical trials of canagli-
flozin (n = 17 596), incidence rates of DKA and related events were
0.52 (n = 4), 0.76 (n = 6), and 0.24 (n = 2) per 1000 patient-years
with canagliflozin 100 and 300 mg and comparator, respectively.34
The majority of canagliflozin-treated patients reporting serious DKA
had associated precipitating factors such as non-compliance with
insulin therapy, and 6 of the 10 canagliflozin-treated patients indi-
cated evidence of autoimmune diabetes (ie, type 1 diabetes, etc.).35
A low frequency of amputation was observed in dapagliflozin-
and placebo-/active comparator-treated patients; however, the num-
ber of patients with amputation events was too low to draw any con-
clusions based on the differences observed in baseline characteristics.
Although drug safety communications have been issued regarding
amputations observed with canagliflozin in the CANVAS trial1; possi-
ble mechanisms are unclear.
Bladder cancer is another safety issue that has been previously
explored, owing to a numerical imbalance observed between
dapagliflozin- and control-treated patients in the new drug application
submitted to the US FDA in 2011.36 In an updated analysis of >9000
patients in the phase IIb/III dapagliflozin trials, 9/5936 and 1/3403
dapagliflozin- and comparator-treated patients, respectively, reported
bladder cancer, with an incident rate ratio of 5.168 (95% CI 0.68-
233.55).37 The totality of the data, with a small number of bladder
cancer cases and the lack of carcinogenic potential of dapagliflozin in
preclinical studies, does not support a causal relationship between
dapagliflozin and increased bladder cancer risk. There was however,
the possibility of ascertainment bias possibly because of a thorough
investigation of microhaematuria from the time of randomization. Blad-
der cancer is being further assessed in a post-authorization safety
study and the DECLARE-TIMI 58 (NCT01730534) trial.
This pooled analysis included treatment-naïve patients and those
receiving multiple background therapies including insulin. All analyses
included data after the initiation of rescue therapy. It is possible that
background therapies may have contributed to the incidence of some
AEs, in particular hypoglycaemia. Another limitation was that the data
were collected from clinical trials and because real-world patients do
not always fit the profile of those included in clinical trials, findings
from this analysis should be applied to the real world with caution.
In conclusion, overall, the proportion of patients experiencing AEs,
including hypoglycaemia, volume depletion, UTI and fracture, was gen-
erally balanced in the dapagliflozin and placebo/active comparator
treatment groups. AEs of renal function with dapagliflozin were related
to transient changes in renal laboratory values. Genital infections were
more frequent with dapagliflozin vs placebo, and this finding is consis-
tent with the previously reported data for SGLT2 inhibitors. A very low
frequency of lower limb amputations was observed in the patients in
the dapagliflozin and control groups. AEs of DKA, ketonuria or meta-
bolic acidosis were rare, with 1 event of DKA reported in the dapagli-
flozin group. No new safety signals for dapagliflozin were identified in
this pooled analysis of a large number of patients.
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